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Abstract: Controlling human pathogenic bacteria is a worldwide problem due to increasing 
bacterial resistance. This has prompted a number of studies investigating peptides isolated from 
marine animals as a possible alternative for control of human pathogen infections. Clavanins 
are antimicrobial peptides isolated from the marine tunicate Styela clava, showing 23 amino 
acid residues in length, cationic properties, and also high bactericidal activity. In spite of clear 
benefits from the use of peptides, currently 95% of peptide properties have limited pharma-
ceutical applicability, such as low solubility and short half-life in the circulatory system. Here, 
nanobiotechnology was used to encapsulate clavanin A in order to develop nanoantibiotics 
against bacterial sepsis. Clavanin was nanostructured using EUDRAGIT® L 100-55 and RS 30 D 
solution (3:1 w:w). Atomic force, scanning electron microscopy and dynamic light scattering 
showed nanoparticles ranging from 120 to 372 nm in diameter, with a zeta potential of -7.16 mV 
and a polydispersity index of 0.123. Encapsulation rate of 98% was assessed by reversed-phase 
chromatography. In vitro bioassays showed that the nanostructured clavanin was partially able 
to control development of Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas 
aeruginosa. Furthermore, nanostructures did not show hemolytic activity. In vivo sepsis bioas-
says were performed using C57BL6 mice strain inoculated with a polymicrobial suspension. 
Assays led to 100% survival rate under sub-lethal sepsis assays and 40% under lethal sepsis 
assays in the presence of nanoformulated clavanin A until the seventh day of the experiment. 
Data here reported indicated that nanostructured clavanin A form shows improved antimicrobial 
activity and has the potential to be used to treat polymicrobial infections.
Keywords: peptides, antimicrobial, nanoparticles, nanobiotechnology
Introduction
The infections associated with human health have led to an increase in pharmacy and 
hospitalization costs and also to a rise in mortality rates.1 Many bacterial lineages 
can be isolated from nosocomial infections, including the Gram-positive bacteria 
Staphylococcus aureus and S. epidermidis as well as the Gram-negative bacteria 
Escherichia coli, Pseudomonas spp., Klebsiella spp., Proteus spp., Enterobacter spp., 
and  Serratia spp.2 Sepsis infections are increasingly common among intensive care 
unit (ICU) patients.3 Worldwide, it has been estimated that 30.8% of these sepsis cases 
could lead to death, whilst in Latin America around 25% of hospital beds are occupied 
by sepsis patients, with 57.3% of cases leading to death.4 
Therefore, many studies have joined the search for innovative antibiotic molecules, 
which include antimicrobial peptides. These compounds display different defense 
mechanisms, including membrane disruption, which plays a critical role against 
pathogenic microorganisms. Clavanin is an antimicrobial peptide family composed 
of four isoforms (“A,” “B,” “C,” and “D”) isolated from Styela clava hemocytes. 
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Clavanins were first described by Lee et al5 who showed 
that clavanins were effective against infections by fungi and 
Gram-positive (including multi-resistant S. aureus, [MRSA]) 
and Gram-negative bacteria. Clavanins have 23 amino acid 
residues in length and are rich in histidine, glycine, and 
phenylalanine amino acid residues, presenting an amidated 
C-terminal.5 Furthermore, some clavanin peptides not only 
display antimicrobial activity but also an immunomodula-
tory activity, which is characterized by host innate humoral 
immune response against pathogenic microorganisms.6 
In sepsis cases, immunomodulatory peptides may selectively 
suppress pro-inflammatory responses and increase the protec-
tive effect of immune activity.6
In spite of clear benefits from the use of bioactive 
peptides, currently 95% of peptide properties have limited 
pharmaceutical applicability due to some characteristics 
such as short half-life in the circulatory system, toxicity, 
uncontrolled release, immunogenicity, and costs for 
therapies.7–9 Another significant problem to be solved consists 
of biodistribution. Proteins and peptides are strongly affected 
by rapid hydrolysis by proteases in the blood stream and 
low permeability across biological barriers.10 Furthermore, 
biodistribution can also be influenced by different factors 
such as physicochemical properties, size, shape, and route 
of administration.11 In this context, injectable nanoparticles 
can be driven to different tissues, since they are directly 
affected by blood vessel endothelium. For example, lungs 
and muscles only allow entrance of molecules of less than 
3 nm, which can be transported across the capillary wall. 
However, the kidneys, liver, and spleen have blood vessels 
with larger pore spaces, allowing the entrance of molecules 
up to 60 nm (hydrodynamic diameter).11
In this regard, some studies have developed strategies to 
protect peptides and proteins against in vivo systems. Among 
them, nanostructures have been considered as efficient carriers 
since they provide higher levels of biodegradability and 
biocompatibility. Recent studies showed nanometric systems 
developed to deliver different compounds involved in the 
treatment of pathologies, among them chemotherapeutic 
molecules, bronchodilators, and antibiotics.12–16
Different nanosystems can be used to prepare drug carriers, 
including polymeric nanoparticles that consist of colloidal 
carrier systems of up to 1,000 nm in diameter.16 In order to 
obtain higher antibiotic therapeutic efficacy and avoid the 
microorganisms’ resistance mechanisms, polymeric systems 
for drug carriers can be rationally designed. Focus should be 
given to peptide protection from the host system, increas-
ing bacterial membrane specificity and controlled release 
to decrease peptide concentrations and number of doses 
needed.12,15 Although nanoparticles containing conventional 
antibiotics have been described, few studies have reported 
nanoparticles containing antimicrobial peptides. In the pres-
ent study, two methacrylate-based polymers, EUDRAGIT® L 
100-55 and RS 30 D, were used. EUDRAGIT® L 100-55 is 
formed by an anionic copolymer based on methacrylic acid 
and ethyl acrylate. Furthermore, EUDRAGIT® RS 30 D is a 
copolymer formed by ethyl acrylate, methyl methacrylate, 
and low content of methacrylic acid ester with quaternary 
ammonium groups.17 The ammonium groups are present as 
salts and make the polymers permeable.17 These polymers 
have been used for pharmaceutical purposes as previously 
described.17,18 These polymers present 99% purity,17,19 sim-
plifying the nanostructuration protocol based on hydropho-
bicity and higher encapsulation efficiency.10,17,19–22 Polymer 
hydrophobicity allows its solubilization on acetone 95% 
and ethanol 5% solution, and further peptide coupling 
occurs after water addition, due to amphipathic properties 
of clavanin used here. Moreover, release assays showed a 
higher stability of methacrylate nanostructures in water, as 
discussed above. This assay provides information about 
storage stability, since the nanostructures were only applied 
to water environment.23
Bi et al24 developed phytoglycogen-based nanoparticles 
containing the antimicrobial peptide nisin, effective against 
Listeria monocytogenes. Furthermore, Liu et al25 showed 
core-shell nanostructured nanoparticles formed from TAT 
sequence (YGRKKRRQRRR) against S. aureus.25 Here, 
methacrylate polymers (EUDRAGIT® L 100-55 and RS 
30 D) were used to encapsulate the antimicrobial and 
immunomodulatory peptide clavanin A, and their activity 
was further evaluated in vitro and in vivo using septicemic 
models. Morphological analysis of encapsulated clavanin A 
indicates particle integrity, stability, and diameter regularity, 
as well as its in vitro and in vivo efficiency. Current analysis 
demonstrates the potential activity of this novel compound 
combination against polymicrobial infection.
Here, a novel antibiotic is examined, for potential use 
against polymicrobial infections that can progress to sepsis 
infections, commonly observed among ICU patients, leading 
to higher mortality rates and ever-increasing hospitaliza-
tion costs. Current antibiotics do not show efficient activity 
against some bacterial species, and a real need for novel 
antibiotic development is necessary. The use of nanotech-
nology associated with antimicrobial peptides as a new tool 
for antibiotic development is proposed. Moreover, poly-
meric EUDRAGIT® nanoparticles with pH dependence and 
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biodegradability were used in order to improve clavanin A 
stability in the host system.
Material and methods
synthesis and peptide purity evaluation 
Clavanin A (VFQFLGKIIHHVGNFVHGFSHVF-NH
2
) 
was synthesized by China Peptides Co., Ltd., using solid 
phase method and F-moc strategies.26 Lyophilized peptide 
was re-suspended in 0.1% TFA (trifluoroacetic acid) and 
further purified using a reverse-phase analytical HPLC 
(high-performance liquid chromatography) Phenomenex 
C
18
 column (4.6 mm ×250 mm), with a linear acetonitrile 
gradient (5%–95%) at a flow rate of 1.0 mL⋅min-1. Peptide 
elution was monitored at 216 and 280 nm absorbance. Mole-
cular mass and purity of synthetic peptide was confirmed 
by MALDI-TOF/TOF™ UltraFlex III (Bruker Daltonics, 
Billerica, MA, USA) analyses. Samples were solubilized in 
α-cyano-4-hydroxycinnamic acid saturated solution (1:3), 
and 1 µL of this solution was applied onto MALDI plate 
type MTP 384 and further air-dried. Mass spectrometer was 
calibrated with Peptide Calibration Standard II (Bruker Dal-
tonics). Theoretical monoisotopic mass value was obtained 
by Protein Prospector (http://prospector.ucsf.edu/prospector/
mshome.htm) and was compared with experimental values 
obtained. For peptide quantification, absorbance measure-
ments at three different wavelengths (205, 215, and 225 nm) 
were performed according to Murphy and Kies.27
Polymeric nanoparticle preparation
Nanostructures were prepared by using 100 µg of synthetic 
clavanin A (in the presence of polymer (EUDRAGIT® L 
100-55) and copolymer (EUDRAGIT® RS 30 D) at different 
ratios (1:3, 1:1, and 3:1 m:m). According to sample analysis 
by atomic force microscopy (AFM), described in the next 
topic, it was determined that only the 3:1 ratio (22.5 mg of 
polymer and 7.5 mg of copolymer) could lead to nanoparticle 
formation. For this reason, this proportion was maintained 
in all experiments described.28 Nanoparticles were prepared 
from oil/water emulsion by using 95% acetone and 5% etha-
nol solution at 1:10 ratio (mass of polymer and copolymer 
for acetone and ethanol solution). Labrafil®M1944CS was 
used as a surfactant at concentration of 1.14 mg⋅mL-1. Aiming 
to improve solubilization, reagents were added to main 
solution following the sequence EUDRAGIT® RS 30 D, 
EUDRAGIT® L 100-55 D, surfactant, and peptide. Further, 
2.25 mL of autoclaved ultrapure water was added, aiming 
to induce nanoparticle aggregation by hydrophobicity.18 This 
solution was incubated at 4°C for 12 hours and  centrifuged 
at 13,400×g for 30 minutes at room temperature to remove 
residues. Then, the supernatant was collected, and the pre-
cipitate discarded. To remove the organic solvents a rota-
evaporation system in Buchi® RIII equipment was used at 
constant pressure (20 in⋅Hg), for 10 minutes at 37°C and 
once more centrifuged at 13,400×g for 30 minutes at room 
temperature in order to remove any residues.
Morphological analysis
Aiming to observe a complete morphological analysis, 
three different methods were used for better understand-
ing nanostructure behavior, including AFM, scanning 
electron microscopy (SEM), and dynamic light scattering 
(DLS).29,30
atomic force microscopy
Nanoparticle diameter (nm) was determined by AFM using 
SPM 9600 equipment (Shimadzu Corporation, Kyoto, 
Japan). Aiming to obtain suitable concentration, samples 
were diluted at 1:100 (µL) sample/ultrapure water ratio, 
with 1 µL of diluted sample applied onto freshly cleaved 
mica-muscovite surface and fixed to metallic sample sup-
port. Images were obtained in dynamic mode, using a probe 
(PPP-NCHR NanoSensors®).31 After drying the samples, 
images with 512 pixels ×512 pixels of resolution, maximum 
dimension of 125 µm ×125 µm, and scan areas of 50 µm × 
50 µm and 10 µm ×10 µm were obtained. SPM-9600 off-line 
software was used in order to adjust the image plane. Particle 
analysis was performed using the same software.
scanning electron microscopy 
For morphological analysis of particles by SEM, a Zeiss DSM 
962 (Carl Zeiss Meditec AG, Jena, Germany) microscope 
was used. Nanoparticles were applied to a clean coverslip and 
partially dehydrated at 37°C for 5 days. After this, pieces of 
the coverslip were affixed to the stubs surface using double-
sided adhesive conductive carbon tape. Stubs were recovered 
with a gold ultra-thin layer (20 nm) using the Sputter Coat 
Emitech K550. SEM images were analyzed and captured, 
and particle shape and size were determined.
Dynamic light scattering
The hydrodynamic diameters of the nanostructures were 
evaluated using a Zetasizer nano ZS ZEN3600 (Malvern 
Instruments, Malvern, UK) DLS instrument equipped with 
a 633 nm (red) He-Ne 4 mW laser. Polyethylene disposable 
cells were used for this analysis. The nanoparticle solution 
was centrifuged at 13,400×g prior to measurement in order 
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to eliminate possible high molecular weight contaminants 
present in the sample solution. The precipitate was discarded, 
and the supernatant was used for analysis. A total of three 
readings were performed using 1 mL of nanoparticle sample 
containing 100 µg⋅mL-1 nanostructured clavanin at 25°C. 
Each reading was composed of 15 measurements of the 
backscattering (173°) intensity collected for 70 seconds by 
an Avalanche photodiode detector. Zetasizer software version 
6.11 was used for data processing and analysis.
Encapsulation efficiency
Encapsulation efficiency was estimated for the total clavanin 
A coupled to fluorescein isothiocyanate (Clav-FITC) applied 
from the nanostructuration process. Before peptide encapsu-
lation, the fluorophore FITC was coupled to clavanin A at a 
1:2 ratio, respectively. After peptide marking, Clav-FITC was 
applied onto a 1 kDa pore-size minidialysis tube for 12 hours 
at 4°C, aiming to remove free FITC. A standard curve using 
FITC coupled to peptide was performed to quantify the free 
peptide after nanostructure release (data not shown). Free 
Clav-FITC was analyzed using spectrofluorimeter (FP 6500; 
JASCO, Tokyo, Japan) coupled to a Peltier temperature 
control system (JASCO).
In vitro peptide release assays
For in vitro peptide release assays, samples were divided 
into 1 mL aliquots containing 100 µg⋅mL-1 of nanostruc-
tured clavanin solubilized in water, being further incubated 
at 37°C. Clav-FITC was applied from the nanostructuration 
process and then collected at intervals of 24 hours during a 
7-day period. In order to separate released Clav-FITC from 
other compounds and residues, all samples were applied in 
Amicon® 10 kDa ultrafilter and centrifuged at 4,400×g for 
10 minutes. Supernatant was discarded and the precipitate 
collected and further analyzed in a spectrofluorimeter (FP 
6500; JASCO) coupled to a Peltier temperature control 
system (JASCO). 
In vitro antibacterial assays
Antibacterial in vitro assays were performed against 
Gram-positive (S. aureus ATCC25923) and Gram-negative 
(E. coli ATCC8739, K. pneumoneae ATCC13885, and 
P. aeruginosa ATCC 27853) bacteria. Aiming to obtain pure 
colonies, bacteria were previously plated and incubated for 
48 hours at 37°C. A single colony was isolated to be rep-
licated in Luria Bertani medium (5 mL) and incubated for 
12 hours at 37°C and 240 rpm. In order to analyze in vitro 
antimicrobial activities, different samples were assayed, 
including nanoparticles without peptide and free clavanin, 
and nanoparticles containing clavanin at a standard concen-
tration of 12 µg⋅mL-1. Chloramphenicol was used as a posi-
tive control. Distilled water was used as negative control. In 
vitro antibacterial activity was evaluated by the analysis of 
the absorbance measurement at 595 nm, every 30 minutes, 
for 12 hours. All assays were performed in enzyme-linked 
immunosorbent assay (ELISA) microplates with 96 wells, 
with 100 µL final volume in each well, and assays were 
performed in triplicate.32
In vivo antibacterial activities
This study was approved by the Animal Use Committee 
(CEUA) at the Institute of Biological Sciences, number 
0177-07, University of Brasilia. In vivo sepsis analysis 
was performed according to the method proposed by 
Moreno et al33 involving intraperitoneal sepsis induction 
in mice using an injection containing a bacteria pool. 
For in vivo experiments, C57BL/6 mice were obtained 
from the Universidade Católica Dom Bosco, housed in 
temperature-controlled cages (22°C–24°C), and received 
food and water ad libitum. Bacteria were previously 
obtained from mice cecum and further filtered, plated in 
BHI (brain–heart infusion) medium and incubated at 37°C 
for 21 hours. Bacterial suspension was centrifuged, and 
precipitate was collected and solubilized in sterile saline 
solution. After this, 60% glycerol was added to this sus-
pension, which was stored at −80°C. In order to prepare 
the suspensions for in vivo assays, one of the aliquots 
was incubated at 37°C for 21 hours. Further suspensions 
were serially diluted (1:2) and then quantified by spectro-
photometer at 595 nm absorbance. Bacterial suspension 
(P. aeruginosa, S. aureus, E. coli, and K. pneumoniae) was 
identified using three different methods: TSI (triple sugar 
iron)-containing agar, SIM (sulfide indole motility), and 
citrate test.34 Bacterial suspensions were quantified with 
4.1×1010 CFU⋅mL-1 concentrations. Next, sepsis severity 
groups were defined according to the amount of suspension 
applied on each mouse. In the lethal group (L), 25 µL of 
1.02×109 CFU bacterial suspension was applied per mouse, 
and in the sub-lethal group (SL) 15 µL of 6.15×108 CFU 
bacterial suspension was applied per mouse. The lethal 
group was considered to present 90%–100% of mortality, 
and the sub-lethal group presented 40%–60% of survival. 
The L experimental group was divided, thus, into six groups 
with five animals in each, and the SL experimental group 
was divided into four subgroups with five animals in each. 
Treatment groups were divided into infected and untreated, 
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infected and treated with nanostructured clavanin A 
(2 µg⋅mL-1), infected and treated with nanostructured clava-
nin A (4 µg⋅mL-1), infected and treated with nanostructured 
clavanin A (12 µg⋅mL-1), infected and treated with empty 
nanostructures, and infected and treated with free clava-
nin (12 µg⋅mL-1). The animals were pretreated according 
to treatment groups. After 15 minutes, the animals were 
infected with bacterial suspension. Then the animals were 
treated according to group, and every 24 hours, each animal 
received the specific treatment established for the group. 
Aiming to estimate the survival function of lifetime data 
obtained from the survival experiment (lethal and sub-lethal 
doses), Kaplan–Meier estimator methodology was used.35
In vitro immunomodulatory assays
Immunomodulatory assays were performed by using RAW 
264.7 murine macrophage-like cells. RAW 264.7 cells were 
obtained from the Cell Bank of Rio de Janeiro (CR108) 
and maintained in supplemented DMEM medium (Gibco®; 
Thermo Fisher Scientific, Waltham, MA, USA) contain-
ing 10% of fetal bovine serum, 100 U⋅mL-1 penicillin and 
100 U⋅mL-1 streptomycin; these cells were then incubated 
in the presence of CO
2
 at 37°C. Cytokine production (tumor 
necrosis factor [TNF]-α, interleukin [IL]-10, and IL-12) was 
evaluated on RAW 264.7 cell culture supernatant. After 
incubation, cells were stimulated with S. aureus and E. coli 
(5×105 CFU⋅mL-1) antigen, with and without recombinant 
interferon (IFN)-γ (10 ng⋅mL-1) (PeproTech, Rocky Hill, 
NJ, USA). After this, aiming to observe a major cytokine 
action (inflammatory TNF-α, IL-12, and regulatory IL-10), 
microplates were incubated for 24 hours (TNF-α and IL-12) 
and 72 hours (IL-10) at 37°C, with 5% CO
2
. TNF-α, IL-10, 
and IL-12 supernatant concentrations were determined 
by ELISA, according to the manufacturer’s specifications 
(PeproTech). Cytokine levels were expressed in picograms 
per milliliter (pg⋅mL-1).36
Results and discussion
Morphological characterization 
of nanoparticles
To prepare methacrylate nanoparticles containing the antimi-
crobial peptide clavanin A, three different ratios of polymers 
EUDRAGIT® L 100-55 and EUDRAGIT® RS 30 D were 
used: 1:3, 1:1, and 3:1. These polymeric nanoparticles con-
sist of a colloidal system, which aims to protect molecules 
or biomolecules, in this case, against the host’s immune 
system and proteinases.12 Figure S1 shows a simple scheme 
for data presentation.
EUDRAGIT® L 100-55 is an anionic copolymer based on 
methacrylic acid and ethyl acrylate. This polymer contains 
free carboxyl groups coupled to ester groups. EUDRAGIT® 
RS 30 D contains ethyl acrylate, methyl methacrylate, and 
methacrylic acid (low concentration). These compounds were 
used to obtain an insoluble polymer with no pH dependence. 
RS 30 D polymer has a quaternary ammonium group in its 
structure, which increases polymer permeability. Using 
these two polymers (EUDRAGIT® L 100-55 and RS 30 D) 
at different concentrations, viable nanostructures for drug 
delivery were obtained.17,19–21 These polymers have been 
widely used for drug carrier development, since they show pH 
dependence, biocompatibility, stability, and polyelectrolysis 
characteristics, which are convenient for gastric or intestinal 
administration.37
Using methacrylate polymer, some studies have shown 
the viability of EUDRAGIT® polymer to encapsulate differ-
ent drugs. Moustafine et al37 showed the use of EUDRAGIT® 
L 100-55 on interpolyelectrolyte complexes, demonstrating 
high structural stability and viability for drug-delivery appli-
cations, since it showed pH dependence, which led to differ-
ential drug release at different pHs, and also biocompatibility. 
Cetin et al20 showed diclofenac sodium encapsulation with 
EUDRAGIT® L 100 and EUDRAGIT® L 100–poly(lactic-
co-glycolic acid) (PLGA) nanoparticles, and the production 
of nanostructures ranging from 241 to 274 nm in diameter.20 
Another study carried out by Yoo et al21 showed the efficacy 
of EUDRAGIT® S 100 nanoparticles. For this, the authors 
encapsulated a model compound (sodium fluorescein or Nile 
red) for vaginal-specific drug-delivery system, and showed 
nanoparticles of 211–331 nm to be potential carriers in topical 
and systemic delivery.21
The use of polymeric nanostructures to encapsulate dif-
ferent drugs has been extensively studied. Cheow et al38 pro-
duced encapsulated levofloxacin in polymeric nanoparticles, 
of poly(ε-caprolactone) and PLGA polymers. Nanostructures 
were 80 and 230 nm in diameter, by DLS.22 Moreover, 
Fontana et al39 presented an interesting study using amoxicillin-
loaded polyethylcyanoacrylate nanoparticles with added 
polyethyleneglycol (PEG), measuring 220–320 nm. Turos 
et al14 proposed penicillin-bonded polyacrylate nanoparticles 
with 25–40 nm.14
The nanoparticles produced in the present study were 
characterized by AFM, SEM, and DLS. AFM analysis for 
the 1:3 polymer ratios did not show structured nanoparticles 
(data not shown). For the 1:1 ratio, no image was obtained 
due to a probable ferrule contamination, in the sample or 
from sample residues attached to the tip-cantilever.40 Image 
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analysis obtained in the 3:1 ratio showed nanoparticles with 
a dry diameter by height of 120 nm (Figure 1A and B) with 
a bimodal Gaussian distribution between 69 and 260 nm 
(Figure S2). In order to confirm the nanoparticle size (at 
3:1 ratio), SEM analyses were also performed and showed 
particles with uniform shapes (Figure 1C and D). In addi-
tion, DLS analyses were performed showing nanoparticles 
with approximately 372 nm in hydrodynamic diameter and 
a unimodal Gaussian distribution (Figure S3A). 
There is a significant difference in the measured ranges 
for the nanoparticle sizes between the methodologies using 
dried (AFM and SEM) and suspended (DLS) samples. Size 
divergence can be explained by conditions for DLS and 
SEM/AFM analyses; in summary, AFM and SEM analyses 
used dried samples, and under these conditions a significant 
decrease in diameter size could be observed.30 DLS analyses 
showed nanoparticle behavior in solution, complementing 
morphological analysis of methacrylated nanoparticles.41 
In this context, Chicea29 compared two biological samples 
(human serum albumin and red blood cells) using DLS and 
AFM methodologies, showing different results, with the 
smallest size being always observed with AFM analysis. 
Turos et al14 demonstrated the importance of DLS and AFM 
for nanoparticle characterization by using polyacrylate nano-
particles containing penicillin.
Another interesting property related to nanoantibiotic 
development is the polydispersity index (PDI). Indeed, previ-
ous studies showed nanoformulations with PDI in the range 
of 0.01–0.50 indicating low aggregation probability, while 
samples with 0.70 or higher PDI indicated a high aggrega-
tion probability correlated to a wide variation in nanopar-
ticle size.42 In this work, a PDI of 0.123 was obtained from 
the DLS measurements, using methacrylate nanoparticles 
with 3:1 EUDRAGIT® L 100-55 and RS 30 D. In the case 
reported here, there is no aggregation probability according 
to nanoparticle PDI. 
This was corroborated by microscopic analyses 
(Figure 1A–D). Nidhin et al43 showed the difference in 
PDI using different polymers and methodologies. These 
authors showed that nanoparticles produced using alginate 
Figure 1 Polymeric nanoparticles were obtained by using polymer and copolymer at 3:1 (w:w) rates, with 100 µg synthetic clavanin a.
Notes: aiming to observe these structures, aFM and seM were used. aFM images were obtained by sPM 9600 (shimadzu corporation, Kyoto, Japan) equipment (A and B) 
using muscovite mica surface. The images were adjusted in the X and Y plane, and poor training removed from lines. scanning area of 50 µm ×50 µm (A) and 10 µm ×10 µm 
(B). seM images (C and D) show the integrity of the nanoparticles containing the peptide clavanin a after partial dehydration for 5 days at 30°c. 
Abbreviations: aFM, atomic force microscopy; seM, scanning electron microscopy.
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 presented 0.31–0.55 PDI, while with chitosan, nanoparticles 
of 0.11–0.48 PDI were observed, and for starch nanoparticles 
the observed PDI was in the range of 0.11–0.27.43 Fontana 
et al39 showed amoxicillin nanoparticles associated with 
PEG. In this case, nanoparticles showed PDI of 0.28–0.60, 
depending on PEG concentration.39 In two other studies using 
EUDRAGIT® nanoparticles, Yoo et al21 presented 0.23 PDI, 
while Cetin et al20 showed PDI of 0.12–0.19, depending 
on nanoparticle size and PLGA to EUDRAGIT® ratios. 
Therefore, methacrylate nanoparticles shown here present 
promising PDI values for injectable antibiotic development, 
since they present stability and no aggregation probability 
according to the nanoparticle PDI.
The zeta potential experiment showed nanoparticles 
with -7.16 mV (Figure S3B). According to the American 
Society for Testing and Materials, zeta potentials above ±30 
show a higher colloidal stability. In this work, nanostructured 
clavanin showed a lower zeta potential, -7.16 mV, but this 
characteristic allowed an anionic charge, lower agglomerate 
formation, and viable PDI values for injectable antibiotic 
development.44 On the other hand, surface charge can affect 
the immune system response against nanoparticles, and posi-
tive nanoparticles charge showed a higher immune response 
when compared with negative or neutral nanoparticles. How-
ever, the optimal charge for nanoparticles has been described 
between +10 and −10 mV, since these charges provide lower 
phagocytosis and probably minimize nonspecific interaction 
between nanoparticles, increasing biocompatibility.45 In this 
context, Nidhin et al43 showed a different zeta potential for 
nanoparticles produced with different polymers. By using 
alginate, the authors found a zeta potential between −11.9 
and −4 mV, while for chitosan nanoparticles, potentials 
of −14 to 1.3 mV were observed, and for starch nanoparticles, 
the value was 13 mV.43 EUDRAGIT® nanoparticles, observed 
by Cetin et al20 demonstrated −1.53 to 3.47 mV of zeta 
potential. When compared with EUDRAGIT® nanoparticles 
found by Cetin et al20 the nanoparticles of the present study 
seem to show better stability for drug-carrier applications, 
since they showed stability to control their interactions with 
plasma proteins and bacterial membrane. This might be an 
indication that a zeta potential of −7.16 mV, a little more 
negative than those observed by Cetin et al20 is related to a 
better stability of the nanoparticles.
Encapsulation efficiency and in vitro 
release control 
Peptide encapsulation efficiency was evaluated by coupling 
FITC fluorophore to clavanin A. Released peptide  evaluation 
was performed according to free peptide obtained after nano-
structuration process by using spectrofluorimeter (FP 6500; 
JASCO) coupled to a Peltier temperature control system 
(JASCO). EUDRAGIT® nanostructures were capable of 
encapsulating 68.7% of clavanin A. Encapsulation efficiency 
could vary according to physicochemical characteristics, such 
as pH, particle surface properties, nanostructuration method-
ology, and surfactant type. These characteristics interfere in 
chemical interactions between drugs and polymers, changing 
the encapsulation efficiency.18 
Schaffazick and Guterres18 discuss efficiency rate for 
drug encapsulation, in a review where they showed dif-
ferent nanoparticles with 80% and 99% encapsulation 
efficiency.18 By using chitosan associated with antitumor 
peptide, Medeiros46 reported up to 80% encapsulation effi-
ciency. Cetin et al20 showed 25%–62% of sodium diclofenac 
encapsulation using EUDRAGIT® associated with PLGA 
polymer and 56%, 69%, and 81% cumulative release for 
EUDRAGIT®/PLGA (20:80), EUDRAGIT®/PLGA (30:70), 
and EUDRAGIT®/PLGA (50:50), respectively, at 72 hours. 
Nassar et al28 obtained 88% of tacrolimus encapsulation 
efficiency using EUDRAGIT® nanoparticles developed with 
similar methodology to our study.28 These rates show that the 
encapsulation rate of clavanin A was increased by the use 
of methacrylate polymers, since 98% of peptide, besides the 
higher concentration of peptide, made it possible to obtain 
nanoparticles with low zeta potential and PDI, showing a 
higher stability. 
After clavanin A nanostructuration, the samples presented 
pH 6.0. Aiming to observe nanostructure behavior at different 
pHs, this parameter was adjusted for basic (above 7.0) and 
acidic (below 5.0). In both cases, polymer precipitation was 
observed, showing clear pH interference (data not shown). 
In general, pH-sensitive structures have acidic or basic 
groups in the structure, which can react to small changes in 
environmental pH.47 Methacrylate structures do indeed have 
an ammonium group on EUDRAGIT® RS 30 D, probably 
responsible for pH modification response.17,47 Moustafine 
et al37 showed that EUDRAGIT® polymers have pH depen-
dence in an application on ibuprofen release. The authors 
demonstrated that in acidic medium (pH 5.5), the polymer 
was completely ionized, which leads to an improvement in 
structure stability and also in slower drug release. Further-
more, by using basic medium (pH 6.8), this same polymer has 
its carboxyl groups ionized, maintaining negative charges and 
further improving ibuprofen release. Yoo et al21 showed that 
EUDRAGIT® S 100 nanoparticles containing two different 
compounds, sodium fluorescein and Nile red, showed a 
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pH-dependence behavior, being stable at acidic pH. How-
ever, when pH was adjusted to neutral, the nanoparticles were 
unstable and drugs were quickly released.21
Release assays were performed by using 100 µg of 
nanostructured clavanin A. Aiming to observe the time 
dependence of release, these structures were evaluated for 
7 days. These assays showed significant peptide release 
for 7 days in water solution, with a major release (69%) of 
encapsulated peptide occurring after 48 hours (Figure 2). 
Release time seems to be essential for evaluating aggrega-
tion and/or particle fusion associated with physicochemi-
cal properties.16,48 Using PLGA nanoparticles containing 
insulin, Wang et al49 also performed release assays with 
azide sodium solution at pH 7.4 containing bovine serum 
albumin. After 7 days, almost half of the nanoencapsulated 
insulin was released.49 Furthermore, Cetin et al20 yielded 
EUDRAGIT® L 100 and EUDRAGIT® L 100–PLGA 
nanoparticles containing sodium diclofenac. In vitro drug 
release was studied at pH 6.8. After 4 hours, 38% of the 
drug was released using EUDRAGIT® L 100 and 47% by 
using EUDRAGIT® L 100–PLGA. Almost complete release 
(98%) of sodium diclofenac in EUDRAGIT® L 100 particles 
was observed after 12 hours. Moreover, different release 
rates were observed in different polymer combinations 
such as EUDRAGIT®/PLGA 20:80 (56%), EUDRAGIT®/
PLGA 30:70 (69%), and EUDRAGIT®/PLGA 50:50 (98%) 
 nanoparticles, respectively. Release control can be influ-
enced, firstly, by drug–polymer association, and afterwards 
by nanostructure behavior in suspension.50
The release rate, both in vivo and in vitro, could be 
dependent on nanoparticle properties such as drug distribu-
tion on the surface and/or in the matrix of the particle, the 
polymer diffusion area, and also the processes of diffusion 
and erosion. Nevertheless, the in vitro assays can demon-
strate the behavior of nanoparticles in a water environment, 
demonstrating cognate stability during storage. Moreover, 
the in vivo analyses showed peptide release in a physiologic 
environment. So these data suggest that in vivo and future 
experiments can provide nanoparticle pharmacokinetics and 
dynamics in physiologic solution.
In vitro bioassays 
In vitro bioassays were performed against E. coli, 
K. pneumoniae, S. aureus, and P. aeruginosa. Obtained 
data showed that nanoparticles containing 12 µg of pep-
tide were able to inhibit 91% of S. aureus development. 
No antibiotic activities were obtained with free peptide at 
the same concentration or by using empty nanostructures. 
These same nanoparticles showed low deleterious activity 
toward K. pneumoniae (20%) and P. aeruginosa (39.8%), 
and E. coli was not affected. Turos et al14 showed poly-
acrylate nanoantibiotics associated with penicillin against 
methicillin-resistant S. aureus (MRSA), while, in this study, 
64 µg⋅mL-1 minimum inhibitory concentration was also 
observed against MRSA.14,15 Another study performed by 
Cheow et al38 showed levofloxacin-loaded polymeric nano-
particles with 0.03 and 0.15 µg⋅mL-1 minimum inhibitory 
concentration and minimum biofilm inhibitory concentration 
against E. coli.38 Furthermore, no hemolytic activities for 
tested samples were observed (Figure S4), suggesting no 
cytotoxic activity against these cells, as previously observed 
by Nassar et al.28 These results demonstrated that nanofor-
mulated clavanin here studied could be a suitable candidate 
for pharmaceutical applications. This experiment associated 
with survival assays displayed in Figure 3 allows peptide 
viability to be inferred.
Recent studies have demonstrated nanoantibiotic 
action against Gram-positive and -negative bacteria. 
Turos et al14 described polyacrylate nanoparticles cova-
lently bound to penicillin prepared using an emulsion 
polymerization method in order to increase antibiotic 
solubility and improve antimicrobial activity against the 
MRSA. Moreover, Rai et al51 reported gold nanoparticles 
(22–25 nm diameter) containing the antibiotic cefaclor, 
which interferes in peptidoglycan layer synthesis, with 
enhanced activity toward S. aureus and E. coli.51 Cheow 
et al38 proposed the use of PLGA  nanoparticles  containing 
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Figure 2 Peptide release assays were performed by using FITc marked eudragit® 
nanoencapsulated clavanin.
Notes: Peptide concentration was calculated by using spectrofluorimeter (FP 6500; 
JascO, Tokyo, Japan). release was performed in distilled water at ph 6.0 and 
temperature 37°c. released peptide concentration (rp) was calculated using the 
standard concentration of free peptide (Fp) released after clavanin a encapsulation 
(ep) according to experimental groups. In summary, rp = ep - Fp.
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the antibiotic levofloxacin, with efficient activity against 
P. aeruginosa when compared with free levofloxacin.38 
Another study using levofloxacin showed the successful 
use of poly(ε-caprolactone) nanoparticles against E. coli 
biofilm formation.52 
In vivo antibacterial analysis
In vivo antibacterial evaluation was performed by survival 
rate in mice submitted to intraperitoneal sepsis induced by 
a polymicrobial pool injection. Challenges on the seventh 
day showed 100% survival for animals undergoing induced 
sub-lethal sepsis (Figure 3), using a bacterial mix containing 
S. aureus, K. pneumoniae, P. aeruginosa, and E. coli, and 
treated nanostructured clavanin A with 0.2 µg⋅kg-1. Sublethal 
sepsis was tested for three different doses of nanostructured 
clavanin A (2, 4, and 12 µg⋅mL-1). Aiming to evaluate 
only higher activity doses, lethal sepsis was tested only for 
nanostructured clavanin 2 µg⋅mL-1. When nanoparticles 
containing clavanin A 1.2 µg⋅kg-1 and 0.4 µg⋅kg-1 were 
used, only 20% of survival was observed. Analysis using 
lethal induced sepsis (Figure 3) showed that 40% of animals 
treated with nanostructured peptide (0.2 µg⋅kg-1) survived 
until the seventh day, and only 20% of animals treated with 
empty nanostructures survived until the seventh day. Free 
peptides did not show survival index in either case. Since no 
polymeric nanoparticles containing antimicrobial peptides 
have been evaluated against sepsis until now, only a few 
studies were found in the literature. Giacometti et al53 showed 
that intravenous doses of the antimicrobial peptides buforin 
II (1 mg⋅kg-1), indolicidin (1 mg⋅kg-1), and KFFKFFKFF 
sequence (1 mg⋅kg-1) were able to increase mouse survival 
rates, showing 33%, 53%, and 66% survival, respectively, 
against 20% survival rate presented by 20 mg⋅kg-1 imipenem 
(positive control). Cirioni et al54 used magainin (1 mg⋅kg-1), 
an antimicrobial peptide, against E. coli septic shock in rat 
model. In that study, the author showed 73.3% survival in 
comparison to 67% obtained by using 60 mg⋅kg-1 of piperacil-
lin, a beta-lactam antibiotic. In Giacometti et al53 and Cirioni 
et al54 free peptides were used to control sepsis infection, at 
peptide concentrations above 1 mg⋅kg-1. Data here reported 
show the antibiotic activity against a bacterial mix containing 
S. aureus, K. pneumoniae, P. aeruginosa, and E. coli using 
1.2 µg⋅kg-1 of nanostructured clavanin A. In this context, 
our peptide showed better activity when nanostructured in 
EUDRAGIT® polymers.
Interactions between nanoparticles and bacterial mem-
branes can improve the therapeutic drug effects, provid-
ing membrane disruption and leading to antimicrobial 
activity.20,23,55 Aiming to observe nanoparticle adhesion 
on bacterial membrane, Dillen et al23 discussed the strong 
interactions between nanoparticles (formed by EUDRAGIT® 
and PLGA + EUDRAGIT®) and bacterial membranes of 
S. aureus and P. aeruginosa. The authors showed that 
the interaction between cationic nanoparticles formed by 
EUDRAGIT® probably provides an enhanced electrostatic 
interaction, making a better adhesion to microorgan-
isms than anionic PLGA nanoparticles.23 Nanoparticles 
were here produced by using EUDRAGIT® L 100-55, an 
anionic polymer and EUDRAGIT® RS 30 D, a polymer 
with a quaternary ammonium group responsible for mak-
ing polymer permeability.17,19 Immunomodulatory assays 
(Figure 4B and C) showed that nanostructures  without 
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Figure 3 survival rate analysis was performed after sub-lethal (A) and lethal (B) sepsis inductions.
Notes: sepsis induction was performed by using a bacterial pool consisting of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The 
free peptide (FP) was compared with nanostructured clavanin a (Ncl), and the free structure (N), which does not contain the peptide. For sub-lethal bioassays, different 
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intervals for up to 24 hours for 7 days. results are expressed as the percentage of survival.
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peptide showed a stimulation of IL-12 and TNF-α cyto-
kines. Lee et al56 showed cytokines stimulation by thiolated 
EUDRAGIT® microspheres used for vaccines containing 
F4 and F18 antigens isolated from E. coli. The authors 
observed cytokine stimulation even using thiolated 
EUDRAGIT® microspheres without the antigens. Further-
more, nanoparticles can provide a stimulation or suppres-
sion effect on the immune system,19,57 which is an important 
point in sepsis medicine, since they can provide a systemic 
inflammatory response syndrome (SIRS) control, avoiding 
septic shock.58
Immunologic in vitro assays
In order to observe whether nanostructured clavanin, in 
addition to antibacterial activities, is able to modulate the 
immune system, an immunomodulator effect analysis was 
performed using LL-37 as control, which is a peptide with 
ability to modulate inflammatory mediators by different cell 
types.59 For this, free clavanin, nanostructured clavanin, and 
nanostructures without clavanin were evaluated according 
to their effects on regulatory (IL-10) and pro-inflammatory 
(IL-12 and TNF-α) cytokine synthesis by RAW 264.7 cells 
(Figure 4). All of them showed 100% increase in stimula-
tion at IL-10 level when compared with negative control 
(untreated RAW 264.7 cells) at 6 hours. This production 
was reduced by 39% after 48 hours by free peptide. No 
significant reductions were observed for nanostructured 
clavanin and nanostructures (Figure 4). On the other hand, 
IL-12 was stimulated by 26% with free peptide treatment 
when compared with LL-37, while nanostructured clavanin 
stimulated IL-12 secretion by 28% when compared with 
LL-37, but after 48 hours stimulation fell 15%. A similar data 
pattern was obtained for TNF-α level. Empty nanostructure 
caused higher TNF-α stimulation in comparison to LL-37, 
free peptide, and nanostructured peptide (Figure 4). These 
cytokines can be effective in immune system modulation in 
response to the excessive immune response caused by SIRS. 
As showed by Moreno et al58 IL-12 cytokine is fundamental 
for an efficient host defense in polymicrobial sepsis, since 
it acts on IFN-γ induction and stimulation of phagocytic and 
microbicidal activities of neutrophils.
In summary, nanostructured clavanin A showed 100% 
IL-10, 28% IL-12, and 8% TNF-α stimulation (Figure 4). 
Nanostructures without peptide showed inflammatory activ-
ity, probably explained by the presence of polymer compound. 
EUDRAGIT® L 100-55 and EUDRAGIT® RS 30 D are meth-
acrylate polymers and can present inflammatory effects on 
the human system when at higher  concentrations.22 Despite 
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stimulation of IL-12, nanostructures associated with 
clavanin A showed a reduced stimulus when compared with 
nanostructures without peptide. During sepsis, the immune 
system response is completely activated, a super stimulation 
of immune system cells starts and results in cytokine imbal-
ance. This leads to an inflammatory process, damaging the 
host system by excessive immune response. In this context, 
sepsis cases are aggravated by SIRS, but this overexpression 
can be decreased by use of immunomodulatory drugs associ-
ated with antibiotic medicine.22,60 Nanostructured clavanin A 
showed both immunomodulatory and antibiotic effects.
Zolnik et al57 revised the interaction of nanoparticles 
and immune system cells. These authors argue that the 
nanoparticles can interact with the immune system 
and present compatibility, influenced by the chemical 
 surface of nanoparticles,61 causing immunostimulation or 
immunosuppression.57,61 In fact, nanostructures can provide 
some antimicrobial activity against lower concentrations of 
bacteria by polymer–bacterial membrane interactions21,30 or 
induce immune response activity in the host system.57 How-
ever, these nanostructures were not able to provide antimicro-
bial activity at higher bacterial concentrations, as shown in 
in-vivo analysis, and cannot show effective modulation activ-
ity in response to the excessive immune response caused by 
SIRS.58,61 In general, nanostructures can stimulate or suppress 
the immune system and show a positive or negative response 
according to the applications of these structures.62 Some 
studies discussed immune system stimulation by meth-
acrylate nanoparticles.20,62–66 Although IL-12 stimulation by 
nanostructures without peptide has been observed (Figure 4), 
this same stimulus was not observed when nanostructures 
were associated with clavanin, probably because clavanin 
A suppresses the effect as shown in Figure 4. Furthermore, 
it is important to report that besides IL-12 stimulation by 
nanostructures without peptide, no cytotoxic effects against 
erythrocytes were observed. The use of EUDRAGIT® 
polymers against inflammatory diseases was also reported 
by Coco et al63 who showed three different nanoparticles 
using EUDRAGIT® S 100 for the ovalbumin (drug model) 
delivery system against colon inflammatory bowel disease. 
Moreover, ibuprofen encapsulated with EUDRAGIT® R 
100 was evaluated for its ocular anti-inflammatory effects, 
showing increased ibuprofen dispersion and higher anti-
inflammatory activity.26
Conclusion
The data reported here showed an increase in clavanin A anti-
microbial and immunomodulatory activity when the  peptide 
was presented in a nanoparticle formulation, providing a 
promising drug against polymicrobial sepsis infection caused 
by S. aureus, E. coli, P. aeruginosa, and/or K. pneumoniae. 
Methacrylate nanoparticles can provide protection, specificity 
and controlled release of the peptide clavanin A. The obtained 
nanoparticles presented morphological characteristics that are 
viable for injectable drug application,44,67,68 since they did not 
show cytotoxic effect and small size; however, further experi-
ments are needed to evaluate the use of methacrylate nano-
particles for this purpose.68 These properties demonstrated 
that the methods employed here in the nanoencapsulation of 
clavanin A have the potential for antibiotic drug design, and 
may be a promising technology for development of drugs 
and biotechnological products. For sepsis infection, the use 
of nanometric structures can provide low toxicity, better 
distribution, and extended treatment, avoiding interruptions 
in treatment.4,12,68
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Figure S2 atomic force microscopy analysis of methacrylate nanoparticles for particles obtained using 3:1 (w:w) of polymer (eudragit® l100-55) and copolymer (eudragit® 
rs30D), showing trimodal gaussian distribution for diameter (69 and 260 nm), with majority showing 120 nm. 
Figure S1 Workflow for clavanin A nonoencapsulation and further morphological and functional characterization. 
Abbreviations: FITC, fluorescein isothiocyanate; IL, interleukin; TNF, tumor necrosis factor.
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Figure S4 hemolytic activity analysis.
Notes: Free peptide (cl) was compared with nanostructures clavanin a (Ncl) and free structure (N), which does not contain the peptide. For bioassays 12 µg of 
nanostructured peptide was used. c+ correspond to positive control by using 100% Triton X-100. c- correspond to negative control that was saline solution.
Abbreviation: abs, absorbance.
Figure S3 Dynamic light scattering analysis of methacrylate nanoparticles was obtained by use of 3:1 ratios of polymer (eudragit® l100-55) and copolymer (eudragit® rs30D). 
(A) a unimodal gaussian distribution showing nanoparticles of approximately 372 nm. (B) experiment showing nanoparticles with -7.16 mV zeta potential. 
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